Please visit answersincme.com/FAH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancer discusses strategies to integrate anti-EGFR therapies into the treatment of metastatic colorectal cancer. Upon completion of this activity, participants should be better able to: Describe the clinical significance of the latest evidence for anti-EGFR-based regimens for patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC); Outline strategies to optimize the integration of anti-EGFR-based regimens into management plans for patients with RAS/BRAF wild-type mCRC; and Review guideline recommendations for the management of RAS/BRAF wild-type mCRC.